Ignite Creation Date:
2025-12-25 @ 5:04 AM
Ignite Modification Date:
2026-05-03 @ 11:31 PM
Study NCT ID:
NCT06498518
Status:
WITHDRAWN
Last Update Posted:
2025-07-11
First Post:
2024-07-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer
Sponsor:
Karen Carty
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
PRIMUS006-2022
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None